drug development, tuberculosis

More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.  

This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.

A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.

As researchers test existing vaccines for nonspecific protection against COVID-19, immunologists are working to understand how some inoculations protect against pathogens they weren’t designed to fend off.

An early-stage, blood-based assay shows potential as a method for sorting patients with suspected TB from those with other respiratory illnesses.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.

The essential nutrient can kill drug-resistant Mycobacterium tuberculosis by producing oxidative radicals that damage DNA.

Understanding the mechanism of a classic tuberculosis treatment could refine future strategies for TB drug development.

A cheap pain reliever that can kill drug-resistant, tuberculosis-causing bacteria may never be tested.

Chemical ecologist Max Suckling at the Institute for Plant and Food Research Ltd., and summer student Rachael Sagar use Pavlovian conditioning to train bees to stick out their tongues, or proboscises, at the scent of odors produced by tuberculosis-causing bacteria.

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.